IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT OPERATION

In re Application of:

Chih-Ming Chen; Joseph Chou and Unchalee Kositprapa

Serial No.: **09/763,831** Group Art Unit: 3745

Filed: **July 11, 2001** Examiner: **Susan T. Tran**

For: **OMEPRAZOLE FORMULATION**

New York, NY 10036
March 24, 2003

Commissioner of Patents & Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

The following statement of relevance is submitted with the accompanying Form PTO/SB/08A.

Document Designation	Relevance
AA U.S.P. 4,045,563	Relates to a substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects.
AB U.S.P. 4,045,564	Relates to benzimidazole derivatives useful as gastric acid secretion inhibitors.
AC U.S.P. 4,182,766	Relates to napth[2,3-d]imidazoles.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner of Patents
Washington, D.C. 20231
on March 24, 2003

Shari Jackson

Shari Jackson

04/02/2003 MAHMED1 00000087 09763831
02 FC:1806 180.00 OP

Document Designation	Relevance
AD U.S.P. 4,255,431	Relates to a gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion.
AE U.S.P. 4,337,257	Relates to gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparations containing same, and method for inhibiting gastric acid secretion.
AF U.S.P. 4,359,465	Relates to methods for treating gastrointestinal inflammation.
AG U.S.P. 4,432,966	Relates to compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating.
AH U.S.P. 4,508,905	Relates to substituted 2-(benzimidazolyl) pyridines.
AI U.S.P. 4,544,750	Relates to certain pyridyl-N-oxide intermediates for the preparation of omeprazole.
AJ U.S.P. 4,620,008	Relates to processes for the preparation of omeprazole and intermediates therefore.
AK U.S.P. 4,636,499	Relates to sulphenamides.
AL U.S.P. 4,686,230	Relates to a picoline derivatives useful as gastric acid secretion inhibitors.
AM U.S.P. 4,738,974	Relates to base addition salts of omeprazole.
AN U.S.P. 4,786,505	Relates to a new pharmaceutical preparation for oral use containing omeprazole.
AO U.S.P. 4,840,799	Relates to a process for preparing rapidly disintegrating particles.
AP U.S.P. 4,853,230	Relates to pharmaceutical formulations of acid labile substances for oral use.
AQ U.S.P. 5,045,321	Relates to a stabilized pharmaceutical composition and its production.

AR U.S.P. 5,093,132	Relates to a stabilized pharmaceutical composition and its production.
AS U.S.P. 5,093,342	Relates to the use of omeprazole as an antimicrobial agent.
AT U.S.P. 5,178,867	Relates to a dosage form for delivering drug in short time period.
AU U.S.P. 5,204,118	Relates to pharmaceutical compositions and methods for treating the symptoms of indulgence.
AV U.S.P. 5,244,670	Relates to an ingestible pharmaceutical composition for treating upper gastrointestinal tract distress.
AW U.S.P. 5,288,506	Relates to antacid compositions with prolonged gastric residence time.
AX U.S.P. 5,304,540	Relates to pharmaceutical compositions and methods for using the same.
AY U.S.P. 5,330,982	Relates to a pharmaceutical composition containing a 5 HT receptor antagonist and a method of treating gastrointestinal disorders therewith.
AZ U.S.P. 5,352,688	Relates to a method for the treatment of bradyphrenia in Parkinson's disease.
BA U.S.P. 5,362,424	Relates to a microencapsulation for controlled oral drug delivery system.
BB U.S.P. 5,385,739	Relates to stable compositions of gastroprotected omeprazole microgranules and process for the production thereof.
BC U.S.P. 5,389,664	Relates to alleviating stomach ulcers in swine.
BD U.S.P. 5,399,700	Relates to method for preparing enteric coated oral drugs containing acid unstable compounds.
BE U.S.P. 5,417,980	Relates to pharmaceutical compositions and methods for treating the symptoms of overindulgence.
BF U.S.P. 5,433,959	Relates to a stabilized pharmaceutical composition.
BG U.S.P. 5,508,041	Relates to microencapsulation for controlled oral drug delivery system.

BH U.S.P. 5,518,730	Relates to a biodegradable controlled release flash flow melt spun delivery system.
BI U.S.P. 5,599,794	Relates to a synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic.
BJ U.S.P. 5,620,964	Relates to compositions for treating and inhibiting gastric and duodenal ulcers.
BK U.S.P. 5,622,717	Relates to ulcer prevention using a melt spun hydrogel.
BL U.S.P. 5,637,320	Relates to a controlled absorption naproxen formulation for once-daily administration.
BM U.S.P. 5,639,478	Relates to a method to stabilize a pharmaceutical composition and its production.
BN U.S.P. 5,693,818	Relates to a process for preparing pure salts of pyridinlymethyl-sulfinyl-1h-benzimidazole.
BO U.S.P. 5,753,265	Relates to a multiple unit pharmaceutical preparation.
CA WO 85/03436	Relates to diffusion coated multiple units dosage form.
CB WO 95/01783	Relates to a new pharmaceutical formulation.
CC WO 95/10264	Relates to a tablet containing enteric granules.
CD WO 95/12590	Relates to a preparation of omeprazole and lansoprazole and intermediates useful therein.
CE WO 96/01612	Relates to a novel drug delivery system.
CF WO 96/01622	Relates to a new oral pharmaceutical formulation containing magnesium salt of omeprazole.
CG WO 96/01623	Relates to multiple unit tableted dosage form.
CH WO 96/24375	Relates to a new pharmaceutical dosage form.

CI WO 96/02535	Relates to a process for synthesis of substituted sulfoxides.
CJ CA 1,127,158	Relates to 2-pyridymethysulfinyl-benzimidazole compounds.
CK CA 1,129,417	Relates to gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)-pyridines, their preparation, pharmaceutical preparations containing same, and method for inhibiting gastric acid secretion.
CL CA 1,234,118	Relates to pyridyl-n-oxide intermediates for the preparation of omeprazole.
CM CA 1,263,119	Relates to production of 2-(2 pyridylmethylsulfinyl) benzimidazole compounds.
CN CA 1,264,751	Relates to base addition salts of omeprazole.
CO CA 1,292,693	Relates to a pharmaceutical preparation containing omeprazole.
CP CA 1,302,891	Relates to pharmaceutical formulations of acid labile substances for oral use.
CQ CA 1,324,758	Relates to transdermal antisecretory agents for gastrointestinal disease.
CR CA 1,338,377	Relates to stabilized pharmaceutical composition and its production.
CS CA 2,037,101	Relates to omeprazole compositions designed for administration in rectum.
CT CA 2,046,364	Relates to galenic process for omeprazole containing pellets.
CU CA 2,083,605	Relates to method for synthesis.
CV CA 2,139,653	Relates to optically pure salts of pyrinylmethyl sulfinly-1H-benzimidazole compounds.
CW CA 2,140,347	Relates to injection and injection kit containing omeprazole and it analogs.
CX CA 2,166,483	Relates to a new pharmaceutical formulation.

CY
CA 2,166,794

Relates to magnesium omeprazole.

CZ
CA 2,170,647

Relates to multiple unit tableted dosage form.

DA
CA 2,193,681

Relates to a new oral pharmaceutical containing magnesium salt of omeprazole.

DB
GB 1,234,058

Relates to pyridylalkyloxy and pyridyalkythioazole derivatives.

DC
EPO 124,495

Relates to omeprazole salts.

EA
L. Olbe, S.E. et al.,
Present Situation and Future
Prospects of Medical Treatment.,
Gastrins and the Vagus,
Academic Press p. 245-250, 1979.

Relates to omeprazole.

EB
Ekenved et al. "Studies with
H 168/68, a Novel Gastric Acid
Secretion Inhibitor., Gut, Vol. 22,
No. 10, October 1981 p. A877.

Relates to omeprazole.

EC
Erik Fellenius et al., Substituted
Benzimidazoles Inhibit Gastric
Acid Secretion by Blocking
($H^+ + K^+$) ATPase., Nature,
Vol. 290, March 12, 1981
p. 159-161

Relates to omeprazole.

ED
Tore Lind, et al., Effect of
Omeprazole – A Gastric Proton
Pump Inhibitor on Pentagastrin
Stimulated Acid Secretion in Man.,
Gut, Vol. 24 p. 270-276, 1983.

Relates to omeprazole.

EE
K-Fr Sewin et al., Effect of Substituted
Benzimidazoles on Acid Secretion in
Isolated and Enriched Guinea Pig Parietal
Cells., Gut, Vol. 24 p. 557-560, June 1983.

Relates to omeprazole.

EF
Haken Larsson et al., Inhibition of Gastric Acid Secretion by Omeprazole in the Dog and the Rat. Gastroenterology, Vol. 85 p. 900-907, October 1983.

Relates to omeprazole.

EG
Walter Londong et al. Dose-Response Study of Omeprazole on Meal-Stimulated Gastric Acid Secretion and Gastrin Release., Gastroenterology, Vol. 85 p. 1373-1378, December 1983.

Relates to omeprazole.

EH
Stanislaw J. et al., Effects of Omeprazole, a Substituted Benzimidazole, on Gastrointestinal Secretions, Serum Gastrin and Gastric Mucosal Blood Flow on Dogs. Gastroenterology, Vol. 86, p. 71-77, January 1984.

Relates to omeprazole.

EI
D.A. Henry et al., Omeprazole: Effects on Oxidative Drug Metabolism., British Journal of Clinical Pharmacology, Vol. 18, p. 195-200, August 1984.

Relates to omeprazole.

EJ
B.K. Sharma et al., Optimal Dose of Oral Omeprazole for Maximal 24 Hour Decrease of Intragastric Acidity. Gut, Vol. 25 p. 957-964, September 1984.

Relates to omeprazole.

EK
H.P.M. Festen et al., Effect of Oral Omeprazole on Serum Gastrin and Serum Pepsinogen I Levels. Gastroenterology, Vol 87 p. 1030-1034, November 1984.

Relates to omeprazole.

EL
Peter Prichard et al. Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosages Gastroenteroloy, Vol. 88 pp. 64-69 January 1985.

Relates to omeprazole.

EM
K.O. Borg and L. Olbe, Omeprazole – A Survey of Preclinical Data, Gastroenterology, p. 15-22, 37-51, 71-77, 79-93, 105-120, June 1985.

Relates to omeprazole.

EN
50th Edition of Physician's, 1996 Desk Reference p. 529—531.

Relates to omeprazole.

EO
K.O. Borg, L. Olbe Proceedings of the First International Symposium on Omeprazole, Supplement to the Scandinavian Journal of Gastroenterolgy, pp. 11-17, 31-38, 54-56, 59-60, 75-76, 77-78, 89-91, 92-98, 99-104, 105-135, 179, 182-183, 187-195, 1996.

Relates to omeprazole.

FA
U.S.P. 6,096,340

Relates to omeprazole formulations.

FB
WO 96/24338

Relates to a new pharmaceutical formulation and process.

FC
EP 1010423 A2

Relates to an oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production.

FD
September 23, 1994 Decision of the Korean Patent Office Regarding Korean Patent No. 55426 with Certified English Translation See page 4, line 13 to page 5, line 8.

Relates to omeprazole formulation.

FE
Korean Patent Application 92-17571 with Certified English Translation

Relates to omeprazole formulation.

Full text copies or abstracts of the above-identified reference were previously supplied in application Serial No. 09/143,167 with the exception of reference FA-FE. Pursuant to 37 C.F.R. 1.98 (d) copies of references AA-EO are not provided with this Information Disclosure Statement because copies of these references were supplied in the parent application, Serial No. 09/143,167. If additional copies are needed, the Examiner is invited to telephone the undersigned and copies will be immediately provided.

Copies of references FA-FE are enclosed. It is respectfully requested that this art be considered by the Examiner in the above-entitled application and made or record therein. Because the first and non-final Office Action has been issued in this matter, a check in the amount of $180.00 is enclosed pursuant to 37 C.F.R. §1.97(c)(2). If any additional fee is due, the Commissioner is hereby authorized to charge Deposit Account No. 08-1540.

Respectfully submitted,



Martin P. Endres
Reg. No. 35,498

MAILING ADDRESS:
HEDMAN & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036
(212) 302-8989